<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="an interesting issue for preventing and controlling the spread of" exact="virus infection," post="either as sole treatment or as a complement of"/>
 <result pre="confirm the antiviral action in cultured cells of LG against" exact="African" post="swine fever virus (ASFV), foot and mouth disease virus"/>
 <result pre="LG against African swine fever virus (ASFV), foot and mouth" exact="disease" post="virus (FMDV), vesicular stomatitis virus (VSV), and swine vesicular"/>
 <result pre="fever virus (ASFV), foot and mouth disease virus (FMDV), vesicular" exact="stomatitis" post="virus (VSV), and swine vesicular disease virus (SVDV), as"/>
 <result pre="disease virus (FMDV), vesicular stomatitis virus (VSV), and swine vesicular" exact="disease" post="virus (SVDV), as well as the inhibitory effect of"/>
 <result pre="page-count: word-count: Introduction Conventional antiviral drugs (AVs) that interfere with" exact="viral" post="proteins or functions have been developed against a number"/>
 <result pre="functions have been developed against a number of different animal" exact="viral" post="diseases, but these compounds often lead to selection of"/>
 <result pre="of compounds targeted against cellular functions required for viruses to" exact="complete" post="their multiplication cycle. Hence, an efficient non-conventional cell-targeted antiviral"/>
 <result pre="multiplication cycle. Hence, an efficient non-conventional cell-targeted antiviral would inhibit" exact="viral" post="entry and/or replication at a non-toxic concentration for the"/>
 <result pre="cell-targeted antiviral would inhibit viral entry and/or replication at a" exact="non-toxic" post="concentration for the cell and, ideally, it would help"/>
 <result pre="ideally, it would help to control a wide variety of" exact="viral" post="diseases and virus strains. Following this approach, we have"/>
 <result pre="lipid molecules can be correlated with different pharmacological effects against" exact="bacterial" post="cells and viruses (Ogita et al., 2004; Hurtado et"/>
 <result pre="2004; Hurtado et al., 2008). We have previously demonstrated that" exact="viral" post="production was strongly inhibited at non-toxic concentrations of LG,"/>
 <result pre="have previously demonstrated that viral production was strongly inhibited at" exact="non-toxic" post="concentrations of LG, in different cell lines infected with"/>
 <result pre="non-toxic concentrations of LG, in different cell lines infected with" exact="African" post="swine fever virus (ASFV), herpes simplex virus (HSV-1), vaccinia"/>
 <result pre="different cell lines infected with African swine fever virus (ASFV)," exact="herpes" post="simplex virus (HSV-1), vaccinia virus (VV), influenza virus, transmissible"/>
 <result pre="with African swine fever virus (ASFV), herpes simplex virus (HSV-1)," exact="vaccinia" post="virus (VV), influenza virus, transmissible gastroenteritis virus and Sindbis"/>
 <result pre="herpes simplex virus (HSV-1), vaccinia virus (VV), influenza virus, transmissible" exact="gastroenteritis" post="virus and Sindbis virus (Hurtado et al., 2008). VPA"/>
 <result pre="enveloped viruses (Vazquez-Calvo et al., 2011). VPA treatment of vesicular" exact="stomatitis" post="virus (VSV)-infected cells reduced viral production without significantly affecting"/>
 <result pre="2011). VPA treatment of vesicular stomatitis virus (VSV)-infected cells reduced" exact="viral" post="production without significantly affecting viral RNA and protein synthesis"/>
 <result pre="stomatitis virus (VSV)-infected cells reduced viral production without significantly affecting" exact="viral" post="RNA and protein synthesis but interfering with both cell"/>
 <result pre="West Nile virus (WNV) (Vazquez-Calvo et al., 2013) and HSV-1" exact="infection" post="(Crespillo et al., 2016). The FASN synthase inhibitor cerulenin"/>
 <result pre="that de novo fatty acid biosynthesis is relevant for numerous" exact="viral" post="infections. Despite the considerable effort invested in new vaccine"/>
 <result pre="importance, such as those caused by ASFV, foot and mouth" exact="disease" post="virus (FMDV), VSV, or swine vesicular disease virus (SVDV),"/>
 <result pre="foot and mouth disease virus (FMDV), VSV, or swine vesicular" exact="disease" post="virus (SVDV), and many aspects regarding their spread and"/>
 <result pre="spread and persistence remain elusive. ASFV causes an important animal" exact="disease" post="for which no effective vaccine or therapeutic treatment is"/>
 <result pre="available (Sanchez-Cordon et al., 2018). Likewise, FMD is the animal" exact="viral" post="disease with the largest economic impact worldwide. Conventional vaccines"/>
 <result pre="(Sanchez-Cordon et al., 2018). Likewise, FMD is the animal viral" exact="disease" post="with the largest economic impact worldwide. Conventional vaccines have"/>
 <result pre="vaccines have allowed FMD control and eventual eradication of the" exact="disease" post="when properly produced and administered, but pose shortcomings such"/>
 <result pre="the need of high-containment facilities for production, short-lived immunity, and" exact="short" post="shelf-life after formulation (Sobrino et al., 2001). A limited"/>
 <result pre="and short shelf-life after formulation (Sobrino et al., 2001). A" exact="limited" post="repertoire of antiviral drugs is available for ASFV and"/>
 <result pre="and Methods Cells and Viruses Vero and COS (both from" exact="African" post="green monkey kidney), BHK21 (baby hamster kidney), and IBRS-2"/>
 <result pre="on COS cell monolayers, as described (Carrascosa et al., 2011)." exact="Type C" post="FMDV C-S8 isolate (Sobrino et al., 1983) and VSV"/>
 <result pre="Pirbright Institute, UK) and SVDV SP93 (Borrego et al., 2002)" exact="viral" post="stocks were produced in IBRS-2 cells. Virus Infection and"/>
 <result pre="al., 2002) viral stocks were produced in IBRS-2 cells. Virus" exact="Infection" post="and Antiviral Treatment Cell monolayers were grown on multiwell"/>
 <result pre="Cultures were then incubated until massive cytopathic effect was observed." exact="Total" post="virus (intracellular and extracellular) production was evaluated by plaque"/>
 <result pre="wells) obtained were subtracted from the background levels (in the" exact="absence of" post="cells) and compared with the data scored in the"/>
 <result pre="of cells) and compared with the data scored in the" exact="absence of" post="drug (100% viability). CC50 values (concentration of AV yielding"/>
 <result pre="or E70 strains, in medium containing the same AV concentration." exact="Total" post="virus produced at 24 h.p.i. was titrated by plaque"/>
 <result pre="SVDV SP93 isolate in medium containing the same LG concentrations." exact="Total" post="virus produced at 24 h.p.i. was titrated by plaque"/>
 <result pre="VPA); controls with viruses incubated in 2% ethanol in the" exact="absence of" post="the drug were included. After 1 h of incubation"/>
 <result pre="samples with those obtained in virus samples incubated in the" exact="absence of" post="the drug (Figure 3). Figure 3 LG, CRL, and"/>
 <result pre="VPA); controls with viruses incubated in 2% ethanol in the" exact="absence of" post="the drug were included (vehicle). At each AV concentration,"/>
 <result pre="of the drug were included (vehicle). At each AV concentration," exact="total" post="virus was titrated by plaque assay. Time of Addition"/>
 <result pre="were further incubated. At different times (from 3 h before" exact="infection" post="to 24 h after infection), AVs were added to"/>
 <result pre="further incubated until 24 h post-infection (h.p.i.), collected, and the" exact="total" post="virus productivity evaluated by plaque assay. Virus-Specific Protein Expression"/>
 <result pre="and the total virus productivity evaluated by plaque assay. Virus-Specific" exact="Protein" post="Expression Vero cells were pre-treated before virus infection with"/>
 <result pre="plaque assay. Virus-Specific Protein Expression Vero cells were pre-treated before" exact="virus infection" post="with 20 mM VPA or 25 μM CRL for"/>
 <result pre="assay. Virus-Specific Protein Expression Vero cells were pre-treated before virus" exact="infection" post="with 20 mM VPA or 25 μM CRL for"/>
 <result pre="1% Triton X100) supplemented with protease inhibitor cocktail tablets (Roche)." exact="Total" post="intracellular proteins (20–30 μg) were separated by 12% polyacrylamide"/>
 <result pre="et al., 2006), and revealed as above. Extraction of Foot" exact="and Mouth Disease" post="Virus RNA and RT-qPCR BHK21 cells were pre-treated with"/>
 <result pre="2006), and revealed as above. Extraction of Foot and Mouth" exact="Disease" post="Virus RNA and RT-qPCR BHK21 cells were pre-treated with"/>
 <result pre="1, 2, 3, and 8 h.p.i, cultures were collected and" exact="total" post="(intracellular and extracellular) RNA was extracted using Tri-Reagent (Sigma)."/>
 <result pre="RNA (Garcia-Arriaza et al., 2004). &quot;In vivo&quot; Model for Foot" exact="and Mouth Disease" post="Virus Inhibition by Lauryl Gallate LG was initially dissolved"/>
 <result pre="et al., 2004). &quot;In vivo&quot; Model for Foot and Mouth" exact="Disease" post="Virus Inhibition by Lauryl Gallate LG was initially dissolved"/>
 <result pre="Tween80: ethanol: saline (1:1:8). Groups of 6–12 8-week-old C57 (B16J)" exact="female" post="mice were inoculated intraperitoneally (i.p.) as described (Baranowski et"/>
 <result pre="Mice were challenged i.p. with 103 or 104 pfu/mouse of" exact="type C" post="FMDV C-S8 and monitored daily for signs of infection"/>
 <result pre="type C FMDV C-S8 and monitored daily for signs of" exact="infection" post="up to 4 days p.i. Control mice were inoculated"/>
 <result pre="end of the experiment, were anesthetized and euthanized. To determine" exact="viral" post="load after LG treatment, three animals per group were"/>
 <result pre="0.05). Results and Discussion Direct Virotoxicity of Antiviral Drugs on" exact="African" post="Swine Fever Virus and Foot and Mouth Disease Virus"/>
 <result pre="and Discussion Direct Virotoxicity of Antiviral Drugs on African Swine" exact="Fever" post="Virus and Foot and Mouth Disease Virus Direct virucidal"/>
 <result pre="of Antiviral Drugs on African Swine Fever Virus and Foot" exact="and Mouth Disease" post="Virus Direct virucidal effect of the AVs selected for"/>
 <result pre="Drugs on African Swine Fever Virus and Foot and Mouth" exact="Disease" post="Virus Direct virucidal effect of the AVs selected for"/>
 <result pre="the AVs selected for this study in ASFV or FMDV" exact="infections" post="was assayed by incubation of virus samples for 1"/>
 <result pre="the compounds in the range of concentrations analyzed. Inhibition of" exact="African" post="Swine Fever Virus by Different Antiviral Drugs We assessed"/>
 <result pre="in the range of concentrations analyzed. Inhibition of African Swine" exact="Fever" post="Virus by Different Antiviral Drugs We assessed the inhibitory"/>
 <result pre="reduction of ASFV production was observed in the presence of" exact="non-toxic" post="concentrations of VPA (IC50: 2.5–3 mM), and of CRL"/>
 <result pre="virus proteins induced in Vero cells at late times of" exact="infection" post="(Figure 4A). No late ASFV proteins (like p17 or"/>
 <result pre="in protein synthesis was consistent with the inhibition observed in" exact="infective" post="virus yield. The low levels of p32 detected, mainly"/>
 <result pre="washed away and the cultures maintained in the presence or" exact="absence of" post="the AV to complete the virus cycle. Cell extracts"/>
 <result pre="maintained in the presence or absence of the AV to" exact="complete" post="the virus cycle. Cell extracts obtained at different h.p.i."/>
 <result pre="late (P17 and P12) ASFV-induced proteins in the presence or" exact="absence of" post="the AV. ASFV-induced proteins are indicated by arrows. Molecular"/>
 <result pre="up to the completion of virus cycle (24 h.p.i.) when" exact="total" post="virus was titrated on Vero cell monolayers. Time 0"/>
 <result pre="virus adsorption (-2 to 0 h.p.i.). Dotted lines indicate the" exact="total" post="virus production in the absence of inhibitor, corresponding to"/>
 <result pre="h.p.i.). Dotted lines indicate the total virus production in the" exact="absence of" post="inhibitor, corresponding to the value at 24 h.p.i. We"/>
 <result pre="action of the AV. As shown in Figure 4B, ASFV" exact="infection" post="was greatly reduced when the AVs were added prior"/>
 <result pre="when CRL was added as early as 0 h after" exact="infection" post="(simultaneous with the virus inoculum), which could support its"/>
 <result pre="a gradual recovery of virus yields, and even a second" exact="infective" post="step was noticed after 15 h.p.i. Combined administration of"/>
 <result pre="even a second infective step was noticed after 15 h.p.i." exact="Combined" post="administration of different inhibitors is one of the strategies"/>
 <result pre="Vleeschauwer et al., 2017). We studied the effect on ASFV" exact="infection" post="of LG, VPA, and CRL, either alone or, searching"/>
 <result pre="VSV is susceptible to this drug while FMDV and SVDV" exact="infections" post="are not affected (Vazquez-Calvo et al., 2011). As shown"/>
 <result pre="Characterization of the Inhibition Exerted by Lauryl Gallate on Foot" exact="and Mouth Disease" post="Virus Infection We further characterized the effect of LG"/>
 <result pre="the Inhibition Exerted by Lauryl Gallate on Foot and Mouth" exact="Disease" post="Virus Infection We further characterized the effect of LG"/>
 <result pre="Exerted by Lauryl Gallate on Foot and Mouth Disease Virus" exact="Infection" post="We further characterized the effect of LG on FMDV"/>
 <result pre="for this virus, that severely impacts global livestock security, is" exact="limited" post="(De Vleeschauwer et al., 2017). To determine the effect"/>
 <result pre="non-structural (3C) FMDV proteins was analyzed at different times after" exact="virus infection" post="in the presence or absence of the AV. As"/>
 <result pre="(3C) FMDV proteins was analyzed at different times after virus" exact="infection" post="in the presence or absence of the AV. As"/>
 <result pre="at different times after virus infection in the presence or" exact="absence of" post="the AV. As expected, the expression of both proteins"/>
 <result pre="consistent with the level of inhibition (1 log.u.) detected in" exact="infective" post="virus production. Likewise, LG transiently inhibited positive strand viral"/>
 <result pre="in infective virus production. Likewise, LG transiently inhibited positive strand" exact="viral" post="RNA synthesis, from 2 to 3 h.p.i., when total"/>
 <result pre="strand viral RNA synthesis, from 2 to 3 h.p.i., when" exact="total" post="and extracellular viruses were analyzed (Figure 5B). At 8"/>
 <result pre="virus was significantly reduced, which might reflect a decrease of" exact="infective" post="virus release in the presence of LG. However, as"/>
 <result pre="decrease of at least 1 log.u. was observed in the" exact="total" post="virus production of two FMDV serotypes in cells infected"/>
 <result pre="Figure 5 Inhibition exerted by LG on FMDV infection. (A)" exact="Protein" post="expression. BHK21 cell monolayers were preincubated or not with"/>
 <result pre="washed away and the cultures maintained in the presence or" exact="absence of" post="LG for 4 h. Cell extracts obtained at different"/>
 <result pre="washed away and the cultures maintained in the presence or" exact="absence of" post="LG for 8 h. Total viral RNA (intracellular and"/>
 <result pre="in the presence or absence of LG for 8 h." exact="Total" post="viral RNA (intracellular and extracellular) was extracted at different"/>
 <result pre="the presence or absence of LG for 8 h. Total" exact="viral" post="RNA (intracellular and extracellular) was extracted at different times"/>
 <result pre="amplified by RT-qPCR. Data are expressed as VRC (number of" exact="viral" post="RNA copies)/ml of total or extracellular virus. Detection limit"/>
 <result pre="are expressed as VRC (number of viral RNA copies)/ml of" exact="total" post="or extracellular virus. Detection limit was 104 VRC/ml. (C)"/>
 <result pre="maintaining the presence of LG up to 24 h.p.i. when" exact="total" post="virus was titrated on BHK21 cell monolayers. Time 0"/>
 <result pre="The effect of time of addition of LG in FMDV" exact="infection" post="revealed that virus productivity was blocked when LG was"/>
 <result pre="that the step inhibited by the drug was late in" exact="infection" post="(considering that the FMDV cycle is completed in about"/>
 <result pre="second virus round is inhibited by LG additions), with the" exact="total" post="virus productivity recovered when LG was added at 20–24"/>
 <result pre="was reported for the inhibitory action of LG on ASFV" exact="infection" post="in Vero cells (Hurtado et al., 2008); in this"/>
 <result pre="maximum virus titer was observed from 15 h.p.i., involving the" exact="viral" post="DNA replication as the LG-sensitive step in virus inhibition."/>
 <result pre="Other Than Lauryl Gallate To determine whether the inhibition of" exact="virus infection" post="was also observed with esters of gallic acid other"/>
 <result pre="Than Lauryl Gallate To determine whether the inhibition of virus" exact="infection" post="was also observed with esters of gallic acid other"/>
 <result pre="cell viability. Neither G nor PG inhibited FMDV growth at" exact="non-toxic" post="concentrations (up to 100 μM) while OG reduced virus"/>
 <result pre="C-S8 strain in medium containing the same gallate esters concentrations." exact="Total" post="virus produced at 24 h.p.i. was titrated by plaque"/>
 <result pre="represented as virus yield (%). &quot;In vivo&quot; Model for Foot" exact="and Mouth Disease" post="Virus Inhibition by Lauryl Gallate C57 mice were chosen"/>
 <result pre="virus yield (%). &quot;In vivo&quot; Model for Foot and Mouth" exact="Disease" post="Virus Inhibition by Lauryl Gallate C57 mice were chosen"/>
 <result pre="studies, as this mouse strain is clinically susceptible for FMDV" exact="infection" post="(Salguero et al., 2005). A preliminary assay for LG"/>
 <result pre="A preliminary assay for LG toxicity in C57 mice revealed" exact="non-toxic" post="working concentrations of up to 200 mg/kg administered twice"/>
 <result pre="survival rate and clinical score. As reported, FMDV produced a" exact="limited" post="mortality in C57 mice, with a survival rate of"/>
 <result pre="(group 0), while inoculation of LG 24 h prior to" exact="viral" post="challenge (group −1) increased survival rate to 70% at"/>
 <result pre="doses conferred similar protection, mice treated with 200 mg/kg showed" exact="lower" post="weights than those treated with 100 mg/kg dose. Figure"/>
 <result pre="groups that were inoculated or not, 24 h previous to" exact="infection" post="(−1) with 100 mg/ml of LG, were bled and"/>
 <result pre="bled and euthanized for further dissection at day 2 p.i." exact="Total" post="(intracellular and extracellular) virus RNA was extracted from blood,"/>
 <result pre="performed. As shown in Figure 7B, a significant reduction of" exact="viral" post="RNA copies (VRC) was found in all samples from"/>
 <result pre="antiviral effect, in a mouse model, reducing FMDV mortality and" exact="viral" post="load in C57 mice when administered 24 h previous"/>
 <result pre="load in C57 mice when administered 24 h previous to" exact="infection" post="and during the infection process. Our results provide further"/>
 <result pre="when administered 24 h previous to infection and during the" exact="infection" post="process. Our results provide further characterization of the antiviral"/>
 <result pre="FMDV infection. Interestingly, LG also reduced the mice mortality upon" exact="infection" post="with FMDV, which causes an economically devastating livestock disease."/>
 <result pre="these compounds in natural hosts as a first line of" exact="disease" post="defense in case of outbreaks and as a vaccine"/>
 <result pre="and/or the supplementary files. Ethics Statement All the experiments with" exact="infectious" post="viruses were conducted in biosafety level 3 facilities and"/>
 <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
 <result pre="Banco Santander Universidades. References References BaranowskiE.MolinaN.NunezJ. I.SobrinoF.SaizM. (2003). Recovery of" exact="infectious" post="foot-and-mouth disease virus from suckling mice after direct inoculation"/>
 <result pre="Universidades. References References BaranowskiE.MolinaN.NunezJ. I.SobrinoF.SaizM. (2003). Recovery of infectious foot-and-mouth" exact="disease" post="virus from suckling mice after direct inoculation with in"/>
 <result pre="PMID: 14512578 BernardesC.AntónioA.Pedroso de LimaM. C.ValdeiraM. L. (1998). Cholesterol affects" exact="African" post="swine fever virus infection. Biochim. Biophys. Acta1393, 19–25. 10.1016/S0005-2760(98)00051-49714715"/>
 <result pre="de LimaM. C.ValdeiraM. L. (1998). Cholesterol affects African swine fever" exact="virus infection." post="Biochim. Biophys. Acta1393, 19–25. 10.1016/S0005-2760(98)00051-49714715 BorregoB.CarraE.Garcia-RaneaJ. A.BrocchiE. (2002). Characterization"/>
 <result pre="of neutralization sites on the circulating variant of swine vesicular" exact="disease" post="virus (SVDV): a new site is shared by SVDV"/>
 <result pre="CarrascosaA. L.BustosM. J.de LeonP. (2011). Methods for growing and titrating" exact="African" post="swine fever virus: field and laboratory samples. Curr. Protoc."/>
 <result pre="Biol.53, 1–14. 10.1002/0471143030.cb2614s53 CrespilloA. J.PraenaB.Bello-MoralesR.LermaL.Vazquez-CalvoA.Martin-AcebesM. A.et al.. (2016). Inhibition of" exact="herpes" post="virus infection in oligodendrocyte cultured cells by valproic acid."/>
 <result pre="1–14. 10.1002/0471143030.cb2614s53 CrespilloA. J.PraenaB.Bello-MoralesR.LermaL.Vazquez-CalvoA.Martin-AcebesM. A.et al.. (2016). Inhibition of herpes" exact="virus infection" post="in oligodendrocyte cultured cells by valproic acid. Virus Res.214,"/>
 <result pre="10.1002/0471143030.cb2614s53 CrespilloA. J.PraenaB.Bello-MoralesR.LermaL.Vazquez-CalvoA.Martin-AcebesM. A.et al.. (2016). Inhibition of herpes virus" exact="infection" post="in oligodendrocyte cultured cells by valproic acid. Virus Res.214,"/>
 <result pre="VleeschauwerA.LefebvreD. J.De ClercqK. (2017). &quot;Antiviral therapies for FMDV&quot; in Foot-and-mouth" exact="disease" post="virus. Current research and emerging trends. eds. SobrinoF.DomingoE. (Northfolk:"/>
 <result pre="inhibition of the replication of haemorrhagic septicaemia virus (VHSV) and" exact="African" post="swine fever virus (ASFV) by extracts from marine microalgae."/>
 <result pre="Comparative inhibitory activity of the stilbenes resveratrol and oxyresveratrol on" exact="African" post="swine fever virus replication. Antivir. Res.91, 57–63. 10.1016/j.antiviral.2011.04.013, PMID:"/>
 <result pre="Garcia-ArriazaJ.ManrubiaS. C.TojaM.DomingoE.EscarmisC. (2004). Evolutionary transition toward defective RNAs that are" exact="infectious" post="by complementation. J. Virol.78, 11678–11685. 10.1128/JVI.78.21.11678-11685.2004, PMID: 15479809 Garcia-BrionesM.RosasM."/>
 <result pre="F.Gonzalez-MagaldiM.Martin-AcebesM. A.SobrinoF.Armas-PortelaR. (2006). Differential distribution of non-structural proteins of foot-and-mouth" exact="disease" post="virus in BHK-21 cells. Virology349, 409–421. 10.1016/j.virol.2006.02.042, PMID: 16624365"/>
 <result pre="contributes significantly to establishment of a bioenergetically favorable environment for" exact="vaccinia" post="virus infection. PLoS Pathog.10:e1004021. 10.1371/journal.ppat.1004021, PMID: 24651651 HakobyanA.ArabyanE.AvetisyanA.AbroyanL.HakobyanL.ZakaryanH. (2016)."/>
 <result pre="significantly to establishment of a bioenergetically favorable environment for vaccinia" exact="virus infection." post="PLoS Pathog.10:e1004021. 10.1371/journal.ppat.1004021, PMID: 24651651 HakobyanA.ArabyanE.AvetisyanA.AbroyanL.HakobyanL.ZakaryanH. (2016). Apigenin inhibits"/>
 <result pre="infection. PLoS Pathog.10:e1004021. 10.1371/journal.ppat.1004021, PMID: 24651651 HakobyanA.ArabyanE.AvetisyanA.AbroyanL.HakobyanL.ZakaryanH. (2016). Apigenin inhibits" exact="African" post="swine fever virus infection in vitro. Arch. Virol.161, 3445–3453."/>
 <result pre="10.1371/journal.ppat.1004021, PMID: 24651651 HakobyanA.ArabyanE.AvetisyanA.AbroyanL.HakobyanL.ZakaryanH. (2016). Apigenin inhibits African swine fever" exact="virus infection" post="in vitro. Arch. Virol.161, 3445–3453. 10.1007/s00705-016-3061-y, PMID: 27638776 HurtadoC.BustosM."/>
 <result pre="PMID: 24651651 HakobyanA.ArabyanE.AvetisyanA.AbroyanL.HakobyanL.ZakaryanH. (2016). Apigenin inhibits African swine fever virus" exact="infection" post="in vitro. Arch. Virol.161, 3445–3453. 10.1007/s00705-016-3061-y, PMID: 27638776 HurtadoC.BustosM."/>
 <result pre="The HIV-1 reverse transcriptase A62V mutation influences replication fidelity and" exact="viral" post="fitness in the context of multi-drug-resistant mutations. Viruses10:376. 10.3390/v10070376"/>
 <result pre="MottolaC.FreitasF. B.SimoesM.MartinsC.LeitaoA.FerreiraF. (2013). In vitro antiviral activity of fluoroquinolones against" exact="African" post="swine fever virus. Vet. Microbiol.165, 86–94. 10.1016/j.vetmic.2013.01.018, PMID: 23415476"/>
 <result pre="23415476 NovellaI. S.CilnisM.ElenaS. F.KohnJ.MoyaA.DomingoE.et al.. (1996). Large-population passages of vesicular" exact="stomatitis" post="virus in interferon-treated cells select variants of only limited"/>
 <result pre="vesicular stomatitis virus in interferon-treated cells select variants of only" exact="limited" post="resistance. J. Virol.70, 6414–6417. PMID: 8709273 OgitaK.KuboM.NishiyamaN.WatanabeM.NagashimaR.YonedaY. (2004). Enhanced"/>
 <result pre="SaizM.De La MorenaD. B.BlancoE.NunezJ. I.FernandezR.Sanchez-VizcainoJ. M. (2003). Detection of foot-and-mouth" exact="disease" post="virus from culture and clinical samples by reverse transcription-PCR"/>
 <result pre="10.1051/vetres:2002059, PMID: 12588687 SalgueroF. J.Sanchez-MartinM. A.Diaz-San SegundoF.de AvilaA.SevillaN. (2005). Foot-and-mouth" exact="disease" post="virus (FMDV) causes an acute disease that can be"/>
 <result pre="A.Diaz-San SegundoF.de AvilaA.SevillaN. (2005). Foot-and-mouth disease virus (FMDV) causes an" exact="acute" post="disease that can be lethal for adult laboratory mice."/>
 <result pre="SegundoF.de AvilaA.SevillaN. (2005). Foot-and-mouth disease virus (FMDV) causes an acute" exact="disease" post="that can be lethal for adult laboratory mice. Virology332,"/>
 <result pre="(FMDV) causes an acute disease that can be lethal for" exact="adult" post="laboratory mice. Virology332, 384–396. 10.1016/j.virol.2004.11.005, PMID: 15661169 Sanchez-CordonP. J.MontoyaM.ReisA."/>
 <result pre="Virology332, 384–396. 10.1016/j.virol.2004.11.005, PMID: 15661169 Sanchez-CordonP. J.MontoyaM.ReisA. L.DixonL. K. (2018)." exact="African" post="swine fever: a re-emerging viral disease threatening the global"/>
 <result pre="Sanchez-CordonP. J.MontoyaM.ReisA. L.DixonL. K. (2018). African swine fever: a re-emerging" exact="viral" post="disease threatening the global pig industry. Vet. J.233, 41–48."/>
 <result pre="J.MontoyaM.ReisA. L.DixonL. K. (2018). African swine fever: a re-emerging viral" exact="disease" post="threatening the global pig industry. Vet. J.233, 41–48. 10.1016/j.tvjl.2017.12.025,"/>
 <result pre="pig industry. Vet. J.233, 41–48. 10.1016/j.tvjl.2017.12.025, PMID: 29486878 SobrinoF.DavilaM.OrtinJ.DomingoE. (1983)." exact="Multiple" post="genetic variants arise in the course of replication of"/>
 <result pre="genetic variants arise in the course of replication of foot-and-mouth" exact="disease" post="virus in cell culture. Virology128, 310–318. 10.1016/0042-6822(83)90258-1, PMID: 6310859"/>
 <result pre="10.1016/0042-6822(83)90258-1, PMID: 6310859 SobrinoF.SaizM.Jimenez-ClaveroM. A.NunezJ. I.RosasM. F.BaranowskiE.et al.. (2001). Foot-and-mouth" exact="disease" post="virus: a long known virus, but a current threat."/>
 <result pre="10.1016/j.antiviral.2013.05.012, PMID: 23735299 Vazquez-CalvoA.SaizJ. C.SobrinoF.Martin-AcebesM. A. (2011). Inhibition of enveloped" exact="virus infection" post="of cultured cells by valproic acid. J. Virol.85, 1267–1274."/>
 <result pre="PMID: 23735299 Vazquez-CalvoA.SaizJ. C.SobrinoF.Martin-AcebesM. A. (2011). Inhibition of enveloped virus" exact="infection" post="of cultured cells by valproic acid. J. Virol.85, 1267–1274."/>
</results>
